Exploring the efficacy and mechanism of action of combined pan-Raf and MEK inhibition in halting the growth of non-V600 BRAF mutated tumors.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.3117
Abstract: 3117 Background: Class 2 & 3 non-V600 BRAF mutations mediate RAF dimerization to hyperactivate the MAPK signaling pathway. Encorafenib (Enco; BRAF monomer inhibitor) + Binimetinib (Bini; MEK inhibitor) elicit responses in 10) vs. Enco+Bini that… read more here.
Keywords: v600 braf; braf; non v600; belva bini ... See more keywords